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Abstract
There is considerable interest in adverse outcome pathways (AOPs) as a means of organizing biological and toxicological 
information to assist in data interpretation and method development. While several chemical sectors have shown considerable 
progress in applying this approach, this has not been the case in the food sector. In the present study, safety evaluation reports 
of food additives listed in Annex II of Regulation (EC) No 1333/2008 of the European Union were screened to qualitatively 
and quantitatively characterize toxicity induced in laboratory animals. The resulting database was used to identify the criti-
cal adverse effects used for risk assessment and to investigate whether food additives share common AOPs. Analysis of the 
database revealed that often such scrutiny of AOPs was not possible or necessary. For 69% of the food additives, the report 
did not document any adverse effects in studies based on which the safety evaluation was performed. For the remaining 31% 
of the 326 investigated food additives, critical adverse effects and related points of departure for establishing health-based 
guidance values could be identified. These mainly involved effects on the liver, kidney, cardiovascular system, lymphatic 
system, central nervous system and reproductive system. AOPs are available for many of these apical endpoints, albeit to 
different degrees of maturity. For other adverse outcomes pertinent to food additives, including gastrointestinal irritation and 
corrosion, AOPs are lacking. Efforts should focus on developing AOPs for these particular endpoints.
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Introduction
Historically, the safety of food additives has been assessed 
according to the risk assessment paradigm described by the 
World Health Organization (WHO) (WHO 2009). Safety 
evaluation of food additives consists of four steps: (1) haz-
ard identification, i.e., the assessment of the intrinsic toxic 
properties of the compound; (2) hazard characterization, 
which includes dose–response assessment, identification 
of critical toxic endpoints and derivation of health-based 
guidance values; (3) exposure assessment, i.e., the estima-
tion of exposure/intake; (4) risk characterization, which inte-
grates the information from the previous steps to evaluate 
the risk associated with the exposure to the food additive. 
Within hazard characterization, an acceptable daily intake 
(ADI) value is established, which is defined as the maximum 
intake level that poses no harm to the consumer upon daily 
exposure over an entire lifetime. Thus, to conclude on safe 
use, the estimated daily intake (EDI) of the consumer result-
ing from the use of a food additive should not exceed the 
ADI (i.e., risk characterization). For hazard identification 
and characterization, several endpoints need to be assessed 
(WHO 2009). The core endpoints are mutagenicity/geno-
toxicity, reproductive toxicity and developmental toxicity, 
and repeated dose toxicity, including carcinogenicity. Evalu-
ation of some of these endpoints, in particular mutagenic-
ity/genotoxicity, is predominantly based on in vitro tests. 
However, the evaluation of systemic endpoints generally 
relies on toxicity studies in laboratory animals. This safety 
assessment paradigm is used worldwide by (inter)national 
regulatory authorities, not only for food additives, but also 
for industrial chemicals, plant protection products, biocides 
and (veterinary) pharmaceuticals (Embry et al. 2014).
In the European Union, approved food additives are 
listed in Annex II of Regulation (EC) No 1333/2008 
(EC1333/2008). All the authorized food additives are 
deemed safe. Indeed, according to the Regulation, “A food 
additive may be included in the Community lists in Annexes 
II and III only if it meets the following conditions […] (a) 
it does not, on the basis of the scientific evidence available, 
pose a safety concern to the health of the consumer at the 
level of use proposed” (EC 1333/2008). In addition, a re-
evaluation of food additives that were already permitted in 
the European Union before 20 January 2009 has been set up 
under Regulation (EU) No 257/2010 and is still ongoing. 
The European Food Safety Authority (EFSA), and previ-
ously the Scientific Committee on Food (SCF), are respon-
sible for the safety assessment as mandated by the European 
Commission. An ADI is usually derived when adequate 
information on toxicity is available. Nevertheless, some 
food additives have no ADI due to low intrinsic toxicity. In 
this case, there is no need for a numerical ADI, as there is 
no safety concern at the reported uses and use levels (EFSA 
2014a). On the other hand, when the toxicity database is not 
adequate to establish an ADI, the safety of the food addi-
tive is assured by calculating the margin of safety (MoS), 
i.e., comparing the highest estimated intake with the lowest 
point of departure (PoD) available. For re-evaluation pur-
poses and new approvals, EFSA published guidance docu-
ments and, if needed, a call for data. The safety assessment 
requires the evaluation of data on toxicokinetics, genotoxic-
ity, subchronic/chronic toxicity, and carcinogenicity (EFSA 
2012). Improvements have been achieved in terms of a more 
flexible and tailor-made testing approach. However, hazard 
identification and characterization for systemic endpoints, 
such as target organ-specific toxicity, reproductive toxicity, 
and developmental toxicity, still rely on animal experimenta-
tion, which, in addition to obvious ethical concerns, can lack 
human relevance (Meigs et al. 2018).
Given the ethical, financial and scientific concerns associ-
ated with traditional animal testing in safety assessment of 
food additives, there is a push towards incorporating more 
non-animal approaches (Blaauboer et al. 2016; EFSA 2009, 
2014b; NRC 2007). In this respect, a roadmap has been pro-
posed in which the focus moves away from the “black box” 
approach inherent to animal toxicity testing towards one 
where understanding the molecular mechanisms of toxic-
ity becomes central (Blaauboer et al. 2016). The roadmap 
formally incorporates knowledge about the progression of 
toxicity events across scales of biological organization that 
lead to adverse outcomes in humans, generally referred to 
as the adverse outcome pathway (AOP) concept. AOPs are 
pragmatic tools to rationally and visually capture existing 
knowledge regarding the mechanistic basis of toxicity. An 
AOP starts from a molecular initiating event (MIE) (i.e., 
a trigger of toxicity) and relies on a series of key events 
(KEs), linked by key event relationships, ultimately result-
ing in a specific toxicological effect (i.e., the adverse out-
come) (Ankley et al. 2010). AOPs are chemical-agnostic 
in that they describe a toxicological process from a purely 
dynamic perspective (Becker et al. 2015; Burden et al. 2015; 
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Edwards et al. 2016; Perkins et al. 2015; Villeneuve et al. 
2014). Information from different sources can be used dur-
ing AOP development, including in silico, in vitro, in vivo 
and epidemiological data (Vinken et al. 2017). AOP devel-
opment ideally complies with guidance from the Organiza-
tion for Economic Cooperation and Development (OECD) 
(OECD 2017). In fact, the OECD, in collaboration with a 
number of other organizations, has established an electronic 
repository for AOPs, called the AOP Wiki. At present, the 
AOP Wiki contains about 280 AOPs for a plethora of toxi-
cological effects (http://aopkb .org). AOPs were intended 
particularly to support regulatory decision-making based on 
the desire to make effective use of mechanistic data, particu-
larly novel data streams that can be generated more rapidly 
and cost-effectively in a high-throughput format, rather than 
relying only on apical outcome data traditionally measured 
in whole-organism toxicity tests (Burden et al. 2015; Dean 
et al. 2017; Delrue et al. 2016; Edwards et al. 2016; Vil-
leneuve et al. 2014). The specific application of an AOP is, 
however, usually dictated by the amount of available experi-
mental and observational data as well as the AOP’s degree 
of maturity (Leist et al. 2017; Vinken et al. 2017).
In the present paper, a recent study performed by the 
expert group on “Adverse outcome pathways and risk assess-
ment” within the task force of “New approaches to chemical 
risk assessment for foods and food ingredients” at the Inter-
national Life Sciences Institute (ILSI) Europe is described. 
Safety evaluation reports of all food additives listed in 
Annex II of Regulation (EC) No 1333/2008 were screened 
to qualitatively and quantitatively characterize the critical 
adverse effects induced by these food additives in labora-
tory animals. Subsequently, possible adverse outcomes were 
benchmarked against available AOPs in the AOP Wiki. The 
goal of this study was threefold, namely (1) to collect the 
ADIs of food additives, (2) to identify the critical adverse 
effects used for the safety assessment, and (3) to investigate 
whether food additives share common AOPs. The outcome 
of this study will shed light onto the potential application of 
AOPs for the safety evaluation of food additives.
Materials and methods
All food additives authorized in the EU according to Regu-
lation (EC) No 1333/2008 and successive amendments are 
included in the present analysis. The data were retrieved 
from safety assessment reports published by regulatory 
authorities [i.e., EFSA/SCF or the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA)] and were listed in 
a Microsoft  Excel® spreadsheet (Table S1; supplementary 
information). The cutoff date for the data included in this 
study is October 2018. Table S1 includes, for all food addi-
tives, E-number, name, chemical abstracts service (CAS) 
number, functional class, ADI (when defined), PoD from 
which the ADI was derived, and adverse outcome used 
to define this PoD. Functional classes of listed food addi-
tives include food colorings (E 100–181), preservatives (E 
200–290), acidity regulators and antioxidants (E 300–385), 
emulsifiers and stabilizers (E 400–495), anti-caking agents 
(E 500–578), flavor enhancers (E 620–641), glazing agents 
and others (E 900 and onwards). Likewise, the type of ani-
mal study, species and reference of the study were recorded. 
EFSA evaluations were used for data collation where pos-
sible. When not available, the evaluations of the SCF or 
JECFA were consulted. For the purpose of this study, the 
adverse outcome on which a current ADI is based was con-
sidered the most relevant and data entry was restricted to 
these critical adverse outcomes.
During the retrieval of the ADIs, different ADI designa-
tions were encountered: (1) EFSA/SCF established a numer-
ical ADI, sometimes a group ADI for food additives sharing 
similar structures or common metabolic pathways; (2) no 
ADI was specified, since the MoS for the ADI resulting from 
the proposed use was considered sufficiently large; (3) no 
ADI was specified, since the compound had been tested and 
was not toxic at the highest dose tested. In Table S1 (supple-
mentary information), a color coding was introduced to dis-
criminate between the different types of adverse outcomes in 
toxicity studies used for the safety assessment. The classes 
were defined as: (1) “no adverse effect at highest dose level” 
(blue); (2) “local toxicity” (green); (3) “non-specific toxic-
ity” (red); (4) “specific systemic toxicity” (orange). The blue 
code (“no adverse effect at highest dose level”) was used 
when the no observed (adverse) effect level (NO(A)EL) of 
the food additive was the highest dose level tested in the ani-
mal studies. In the vast majority of these cases, the NOAEL 
was above or close to the limit dose of 1000 mg/kg body 
weight/day. The green code (“local toxicity”) was applied to 
effects, such as local irritation of the stomach or other parts 
of the gastrointestinal tract, as well as for effects like laxa-
tion and loose stool, where it was assumed and likely that 
the observation is due to a local effect. The red code (“non-
specific toxicity”) was used for adverse effects for which no 
organ-specific toxicity or any specific mode-of-action could 
be identified, such as reduced body weights, body weight 
gain, reduced food consumption and lower litter size. The 
orange code (“specific systemic toxicity”) was used when 
adverse effects were observed in a specific organ or system. 
A grey color was used in situations where no numerical ADI 
was set because no adverse effects were reported in toxi-
cological studies and the current exposure does not raise a 
safety concern.
The aforementioned classification of chemicals by 
adverse effects allowed for a general analysis of common 
types of critical endpoints used for the safety evaluation 
of food additives, functional additive classes and toxic 
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potencies. The identified adverse outcomes were bench-
marked against available AOPs in the AOP Wiki (http://
aopkb .org/) in October 2018. More specifically, AOPs 
applicable to rodents and, if available, humans, were identi-
fied by searching for particular key words in AOP titles and 
abstracts, such as “epithelial hyperplasia”, “fetal weight” and 
“hepatotoxicity”. Since AOPs in the AOP Wiki significantly 
differ in degree of maturity, only those that were sufficiently 
developed and documented (i.e., those with defined MIE, 
KEs and adverse outcome) were considered in this study.
Results
Overview of critical toxic endpoints used 
for the safety assessment of food additives currently 
authorized in the EU
Table S1 (supplementary information) summarizes the tox-
icity data collected from safety evaluations of food additives 
and forms the basis of this study. The resulting database con-
tains 326 food additives of which the majority are emulsi-
fiers and stabilizers (87), acidity regulators and antioxidants 
(58) (Fig. 1a). For 35%–70% of the food additives in each 
category, no specific toxicity study was available to establish 
a chemical-specific ADI and/or to assign an adverse out-
come. Of the 133 chemicals for which a PoD was available, 
all but six additives had NOAELs as a PoD. For the remain-
ing additives, the LOAEL or benchmark dose lower confi-
dence limit (BMDL) values were used to derive an ADI. Of 
the PoD values, ammonia caramel (E 150c) had the highest 
PoD (20,000 mg/kg body weight/day in rats) and the ferro-
cyanides (E 535–538) had the lowest PoD (4.4 mg/kg body 
weight/day in rats). Food additives in the acidity regulators 
and antioxidants, colorings, preservatives and anti-caking 
agents functional classes were found to have the lowest 
PoDs, although the range in PoD values varied by up to four 
orders of magnitude (Fig. 1b). Of the identified PoD val-
ues below 50 mg/kg body weight/day, the majority were for 
metal-containing compounds and the predominant adverse 
effects were developmental and neurodevelopmental toxic-
ity. These effects included preweaning mortality and postna-
tal growth retardation in a two-generation reproduction and 
developmental toxicity study for hexamethylene tetramine (E 
239) and neurodevelopmental effects in offspring of mice in 
a two-generational reproductive toxicity study for aluminium 
sulphate (E 520). Moreover, some food additives were found 
to be nephrotoxic, including sodium, potassium and calcium 
ferrocyanide (E 535, E 536, and E 538).
As with PoDs, less than half of the food additives have 
a numerical ADI. In fact, 196 of the 326 food additives 
(i.e., 60%) do not have a numerical ADI. The high num-
ber of food additives without an ADI assigned is due to 
several reasons. This includes the fact that the available 
Fig. 1  Classification of 326 food additives into functional classes (a) and associated NOAEL for setting the ADI (b), where available and in 
comparable units (mg/kg body weight/day)
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toxicological data are insufficient to establish an ADI, 
while the level of exposure to the food additive is not of 
safety concern when considering the current uses and use 
levels. This is the case for thermally oxidized soya bean 
oil interacted with mono- and diglycerides of fatty acids (E 
479b) and iron tartrate (E 534), for which EFSA concluded 
that the MoS calculated comparing the highest estimated 
exposure and the lowest available NOAEL is sufficiently 
high, and therefore there is no safety concern for the use 
and use level proposed (EFSA 2015, 2018). It should be 
noted that despite not having an ADI, the adverse effects 
observed in toxicity studies with these food additives were 
still considered for possible association with an existing 
AOP. For the vast majority of food additives, an ADI is 
not deemed necessary because no toxic effects were seen at 
the highest tested dose in animal studies and the exposure 
data indicate that there is no safety concern at the currently 
reported uses and use levels. Some of these food additives 
are authorized at quantum satis in specified food catego-
ries, which means that no maximum level is specified by 
the Regulation. This situation occurs for ascorbic acid and 
related salts (E 300–302), salts of lactate (E 325–327), 
salts of malate (E 350–352) or citric acid and related salts 
(E 331–333). This lack of toxicity even at high dose levels 
implies there is no concern over use of such compounds 
as food additives, but also that in most cases, the available 
data do not provide critical adverse effects that could be 
subject to AOP analysis. It is therefore not surprising that 
60% of the food additives analyzed in this study do not 
have an ADI established and this confirms that, in contrast 
to pesticides for example, food additives are not expected 
to have toxicity.
The remaining 40% of food additives presented in 
Table S1 (supplementary information) do have a numerical 
ADI, but do not necessarily have specific toxicities associ-
ated with them. The first of three categories of food additives 
with ADIs comprises of food additives for which the numeri-
cal ADI is based on a NOAEL that is the highest dose level 
tested. For these chemicals, no adverse effects are observed 
at the highest dose level tested, which is used as the PoD 
to establish the numerical ADI. This situation is observed, 
for instance, for polyglycerol polyricinoleate (E 476). The 
ADI of 25 mg/kg body weight/day is based on the only dose 
level tested of 2500 mg/kg body weight/day in a 2-year com-
bined chronic toxicity/carcinogenicity study in rats that did 
not reveal adverse effects (EFSA 2017). Logically, for these 
chemicals, the PoD does not provide input for evaluating the 
connection with existing AOPs.
The second group of food additives with a numerical ADI 
includes those for which the ADI is based on a non-specific 
toxic endpoint, such as weight loss, soft stool or diarrhea. 
For example, a reduction in body weight gain is observed in 
rats exposed to sucralose (E 955) and sucrose esters of fatty 
acids (E 473). These types of adverse effects are considered 
not sufficiently specific to relate to an existing AOP.
The third group comprises food additives that have a 
numerical ADI that is based on a specific adverse effect, 
such as hepatotoxicity, nephrotoxicity, reproductive toxic-
ity, carcinogenicity or immunotoxicity. These food additives 
provide useful input to analyze the potential of linkage of the 
adverse effects with existing AOPs, and therefore illustrate 
the possible value of AOPs in the safety evaluation of food 
additives. This third group comprises 71 out of the 326 food 
additives analyzed (22%). Figure 2 summarizes the catego-
ries of adverse effects associated with food additive exposure 
in toxicity studies.
Food additives associated with specific toxicity
An analysis of the types of adverse outcomes associated with 
food additive exposure was carried out using the data for 
the 71 food additives for which a specific adverse effect was 
described, 14 of which had no established ADI. The adverse 
outcomes of the 71 food additives were related to various 
organs and systems, including the liver, kidney and cardio-
vascular system, as well as developmental and reproductive 
processes and the endocrine system. Effects on the liver, the 
kidneys, the cardiovascular system, lymphatic circulation 
and developmental processes/reproductive system are listed 
in Tables 1, 2, 3, and 4, respectively.   
In addition, there were effects on hormonal systems, like 
on the thyroid for butylated hydroxytoluene (E 321). For 
several food additives, local irritation and/or corrosivity or 
diarrhea and/or vomiting were reported, which, depending 
on the underlying mode-of-action, may be related to non-
specific effects or present, for example, possible immuno-
toxicity or gastrointestinal toxicity. Only in two cases, the 
critical toxic endpoint was carcinogenesis, namely for dime-
thyl dicarbonate (E 242) and saccharins (E 954). Increased 
incidence in hepatocellular adenomas and carcinomas has 
been reported in only one sex of one species of animals (i.e., 
female F344 rats) exposed to one of the reaction products 
of dimethyl dicarbonate (E 242), namely methyl carbonate. 
Fig. 2  The type of toxicity associated with exposure to each of the 
326 food additives has been categorized into five categories and sum-
marized in a pie chart. “Not applicable” refers to food additives for 
which an ADI is not deemed necessary
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Table 1  Effects of food additives on the liver
Effect Food additive
Changes in clinical chemistry (increases in alanine aminotrans-
ferase or alkaline phosphatase levels)
Lycopene (E 160d), iron tartrate (E 534), neotame (E 961), oxidized polyethyl-
ene wax (E 914), annatto, bixin, norbixin (E 160b)
Increased serum bile acid levels Iron tartrate (E 534)
Hepatocellular hypertrophy Annatto, bixin, norbixin (E 160b)
Hepatocellular vacuolation Paprika extract, capsanthin, capsorubin (E 160c), microcrystalline wax (E 905)
Focal liver necrosis Annatto B (E 160b), hydrogenated poly-1-decene (E 907)
Leucocyte infiltration Brown HT (E 155)
Hepatotoxicity Alpha-tocopherol (E 307)
Fatty liver Oxidized polyethylene wax (E 914)
Table 2  Effects of food additives on the kidneys
Effect Food additive
Altered kidney weight Sorbitan monopalmitate (E 495), iron tartrate (E 534), annatto, bixin, norbixin (E 160b), steviol glycosides (E 960), 
litholrubine BK (E 180)




Altered urinalysis Annatto, bixin, norbixin (E 160b), beta cyclodextrin (E 459)
Nephrocalcinosis Phosphoric acid (E 338), sodium phosphates (E 339), potassium phosphates (E 340), calcium phosphates (E 341), 
magnesium phosphates (E 343)
Nephrosis Sorbitan monopalmitate (E 495), sorbitan monostearate (E 491), sorbitan tristearate (E 492), sorbitan monolaurate (E 
493), sorbitan monooleate (E 494), sorbitan monopalmitate (E 495), ponceau 4R, cochineal red A (E 124)
Table 3  Effects of food additives on the cardiovascular system or lymphatic circulation
Effect Food additive
Altered heart weight Brown HT (E 155)
Arrhythmia Calcium sulphate (E 516), calcium chloride (E 509)
Hematological changes Propyl gallate (E 310), tertiary-butyl hydroquinone (E 319), butylated hydroxytoluene (E 321), hydro-
genated poly-1-decene (E 907), propane-1,2-diol (E 1520)
Lowered hemoglobin levels Azorubine and stannous chloride (E 512), methemoglobin formation reported for potassium nitrite (E 
249), sodium nitrite (E 250), sodium nitrate (E 251), potassium nitrate (E 252)
Changes in leucocyte/neutrophil counts Sorbitan monopalmitate (E 495), iron tartrate (E 534), ethyl lauroyl arginate (E 243), brown HT (E 
155)
Table 4  Effects of food 
additives on developmental 
processes and the reproductive 
system
Effect Food additive
Testicular toxicity Cyclamates (E 952)
Retarded growth of the offspring Hexamethylene tetramine (E 239), butylated hydroxytoluene (E 321)
Cystic ovaries Brown HT (E 155)
Altered ovary weight Steviol glycosides (E 960)
General reproductive and devel-
opmental effects
Butylated hydroxytoluene (E 321) and neurodevelopmental changes 
reported for aluminium (E 173), aluminium salts (E 520-523), gluta-
mates (E 620-625)
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EFSA noted that there was no genotoxicity concern for 
methyl carbonate and that the exposure remains below the 
threshold of toxicological concern of 30 µg/kg body weight/
day for Cramer class I substances. This means that there 
is no indication for a safety concern for the use of dime-
thyl dicarbonate (E 242) as a food additive at its currently 
reported uses and use levels. Saccharin (E 954) has been 
shown to be a non-genotoxic carcinogen at only one site in 
only one sex of one species of animals (i.e., bladder of male 
rats). Considering the weight-of-evidence, the SCF stated 
that it is unlikely that the tumors in the male rat bladder are 
of relevance for humans. However, the SCF, as a matter of 
prudence, decided to take these lesions into account in set-
ting an ADI for saccharins (E 954).
Screening of the AOP Wiki for AOPs relevant to food 
additives
The AOP Wiki contains about 280 AOPs for a broad vari-
ety of adverse effects in human toxicology and ecotoxicol-
ogy, whereby both general and organ-specific toxicities are 
considered (http://aopkb .org/). The toxicological endpoints 
evaluated in animal studies and used in the safety evalua-
tion of food additives can be easily related to the adverse 
outcome described in an AOP, albeit to a diverging extent 
of detail or completeness. On the other hand, no information 
could be found on the MIEs in the safety evaluation reports 
of the food additives included in this study. Therefore, it is 
not possible to unequivocally link existing AOPs to adver-
sity induced by food additives in laboratory animals. Nev-
ertheless, several available AOPs link to specific toxicologi-
cal endpoints identified in this study (Table 5). Numerous 
AOPs relate to toxicity in liver and kidney, which have been 
identified as potential target organs for some food additives. 
Annatto B (E 160b), lycopene (E 160d) and iron tartrate (E 
534) increase levels of aminotransferases, which is a general 
marker of liver toxicity, or cause undefined hepatotoxicity, 
as holds for alpha-tocopherol (E 307). Liver steatosis can be 
triggered by various MIEs, all of which have been embed-
ded in different AOPs (AOP34/36/57/58/59/60/61/62/232) 
and was found to be induced by oxidized polyethylene wax 
(E 914). Iron tartrate (E 534), oxidized polyethylene wax 
(E 914) and neotame (E 961) increases levels of bile acids 
and/or alkaline phosphatase, which are clinical indicators of 
cholestasis, for which an AOP (AOP27) is available.
For kidney, specific toxic manifestations are less delin-
eated compared to liver, both in the EFSA/SCF/JECFA 
safety evaluation reports of the food additives as well as 
in the AOPs in the AOP Wiki. In fact, there are several 
AOPs describing nephrotoxicity (AOP33/105/116/128/138
/177/186/256/257/258), all developed to a different degree 
of maturity. As is the case for hepatic adversities, none of 
these kidney-related AOPs are unambiguously applicable 
to food additives for which various signs of renal toxicity 
have been reported, such as increased excretion rate [sodium 
ferrocyanide (E 535), potassium ferrocyanide (E 536) and 
calcium ferrocyanide (E 538)], altered urinalysis [Annatto 
B/C (E 160b) and beta cyclodextrin (E 459)] and accumu-
lation of eosinophilic material [beta-apo-8′-carotenal (E 
160e)]. Nephrosis and nephrocalcinosis were identified as 
critical endpoints for several food additives, among which 
most structurally related and some only at the highest dose 
tested, including Ponceau 4R (E 124), sorbitan monostearate 
(E 491), sorbitan tristearate (E 492), sorbitan monolaurate 
(E 493), sorbitan monooleate (E 494) and sorbitan monopal-
mitate (E 495) for calcinosis, and phosphoric acid (E 338), 
sodium phosphates (E 339), potassium phosphates (E 340), 
calcium phosphates (E 341) and magnesium phosphates (E 
343) for nephrocalcinosis. However, no AOPs are presently 
available for these specific adverse outcomes in the AOP 
Wiki.
Other AOPs that can be linked to critical toxic endpoints 
of food additives include:
• Testicular toxicity (AOP18/66/67/68/74/212) for cycla-
mate (E 952).
• Neurodevelopmental changes or toxicity (AOP8/12/13/1
7/42/48/54/134/152) for aluminium (E 173), aluminium 
sulphate (E 520), aluminium sodium sulphate (E 521), 
aluminium potassium sulphate (E 522), aluminium 
ammonium sulphate (E 523), sodium aluminium phos-
phate acid (E 541), glutamic acid (E 620), monosodium 
glutamate (E 621), monopotassium glutamate (E 622), 
calcium diglutamate (E 623), monoammonium glutamate 
(E 624) and magnesium diglutamate (E 625).
• Hematological changes and/or toxicity (AOP31) for ethyl 
lauroyl arginate (E 243), propyl gallate (E 310), tertiary-
Table 5  AOPs relevant to food 
additives available in the AOP 
Wiki
Toxicological endpoint AOP number in AOP Wiki
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butyl hydroquinone (E 319), butylated hydroxytoluene 
(E 321), sorbitan monooleate (E 494), iron tartrate (E 
534), hydrogenated poly-1-decene (E 907) and propane-
1,2-diol (E1520).
• Methemoglobin formation (KE in AOP31) for potassium 
nitrite (E 249), sodium nitrite (E 250), sodium nitrate (E 
251), and potassium nitrate (E 252).
• Reduced hemoglobin levels (KE in AOP31) for azoru-
bine (E 122) and stannous chloride (E512).
Only for two food additives, the critical toxic endpoint 
identified in the safety evaluation is carcinogenesis, namely 
dimethyl dicarbonate (E 242) (i.e., liver) and saccharins 
(E 954) (i.e., bladder). As previously mentioned, methyl 
carbonate [i.e., one of the reaction products of dimethyl 
dicarbonate (E 242)] was found to bioaccumulate in the 
liver, which leads to inflammation and hyperplasia, and 
ultimately to liver adenomas and carcinomas. This could 
be covered by AOP220. Other cancer-related AOPs in the 
AOP Wiki apply to other organs such as lung (AOP272), 
breast (AOP199/200), ovaries (AOP165), uterus (AOP167) 
and the hematopoietic system (AOP202). No AOPs related 
to bladder cancer were found.
It should be noted that for several food additives, such 
as iron tartrate (E 534), annatto, bixin, norbixin (E 160b), 
brown HT (E 155) and butylated hydroxytoluene (E 321), 
the safety assessment relied on a number of systemic adverse 
effects, involving different target organs. This means that 
different AOPs, which may or may not be mutually related, 
could be potentially used for the evaluation of a specific 
food additive.
For some food additives, the critical endpoints are local 
effects. For example, gastrointestinal irritation or corro-
sivity have been identified as the critical effects of acidic 
and alkaline food additives, including sulfur oxide (E 220), 
sodium sulphite (E 221), sodium bisulphite (E 222), sodium 
metabisulphite (E 223), potassium metabisulphite (E 224), 
calcium sulphite (E 226), calcium hydrogen sulphite (E 
227), potassium bisulphite (E 228), hydrochloric acid (E 
507) and sulphuric acid (E 513). Likewise, propionic acid 
(E 280), sodium propionate (E 281), calcium propionate (E 
282) and potassium propionate (E 283) have been associated 
with local effects in the esophagus. AOPs for all these local 
endpoints are currently lacking.
Discussion
In the last 2 decades, a clear tendency has emerged to move 
to the use of mechanistic and 3R (i.e., replacement, refine-
ment and reduction of animal studies)-based strategies for 
the safety evaluation of chemicals. This paradigm shift has 
been reinforced by the introduction of AOPs, which are 
gaining momentum worldwide. The application of AOPs 
in chemical risk assessment involves the possibility to pre-
dict apical toxic outcomes using molecular effects, which 
runs in parallel with the development and implementation 
of mechanistic approaches in toxicity testing (Willet et al. 
2018). It should, however, be stressed that AOPs cannot be 
used as stand-alone tools, as they consider only the toxicody-
namic basis of the adverse outcome. AOPs should therefore 
be combined with information on other critical aspects for 
sound safety evaluation, including exposure and kinetics as 
well as definitions of the critical effect and dose–response 
assessments. Together, a suitable PoD for risk assessment, 
such as a NOAEL or BMDL, may be established. AOPs 
have been proposed as frameworks to develop integrated 
testing strategies (Vinken et al. 2017). Such AOP-based 
integrated approaches to testing and assessment have been 
introduced and successfully applied in the cosmetics field, 
in particular for predicting and testing skin sensitization by 
identifying the possible hazards for this selected endpoint 
(OECD 2016). The AOP for the latter has been recently 
used as the basis for the establishment of a proposed AOP 
for allergic sensitization to food (Van Bilsen et al. 2017). 
There is high potential for the application of the AOP frame-
work also in food chemical risk assessment. This has been 
illustrated by a number of recent publications, which show 
that PoDs derived from molecular endpoints, such as from 
toxicogenomic data and/or quantitative in vitro-to-in vivo 
extrapolation approaches, are often in the range of PoDs 
derived from traditional apical toxic endpoints (Levorato 
et al. 2019 and references therein). Driven by these recent 
developments, the task force of “New approaches to chemi-
cal risk assessment for foods and food ingredients” at ILSI 
Europe installed an expert group, entitled “Adverse out-
come pathways and risk assessment”, in 2017 with the aim 
of exploring the potential role of AOPs for contemporary 
safety evaluation in the food sector. This was achieved by 
first mapping the critical toxicological effects upon which 
the safety assessment of European-approved food additives 
is based. The expert group then mapped coverage of these 
adverse effects by AOPs publicly available in the AOP Wiki.
Safety assessment of food additives is currently per-
formed according to the approach outlined by the WHO 
(2009). Of note, EFSA, in its guidance for submission of 
food additive evaluation, stressed the importance of adopting 
testing strategies in line with the 3R concept, also indicating 
the use of mode-of-action, and thus potentially of AOPs, in 
the process (EFSA 2012). This EFSA guidance indicates, 
for example, that use of mode-of-action is important to set 
a group ADI for compounds with, or presumed to have, a 
common mode-of-action. Another area where AOPs may be 
relevant in the safety evaluation of food additives is geno-
toxicity testing. The above-mentioned EFSA guidance states 
that insight into the mode-of-action, including, for instance, 
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metabolic pathways involved in bioactivation, may be essen-
tial to define the in vitro assay appropriate for detection of 
possible genotoxicity. Modifications of the testing strategy 
are required when standard in vitro systems used for geno-
toxicity testing lack specific metabolic pathways or cannot 
mimic specific modes-of-action (EFSA 2012). This would 
hold for all cases where in vitro data are to be used in the 
process of safety evaluation. Clearly, the use of AOPs can 
support selection of the most appropriate in vitro systems.
In the guidance document, EFSA also mentions the use 
of the mode-of-action in a proposed tiered approach in 
which results of equivocal relevance in a preferred species 
may trigger use of such information in risk assessment. An 
example would be species-specific differences in the mode-
of-action underlying chemical-induced induction of kidney 
tumors only in male rats, but not in female rats or humans 
related to expression of alpha 2u-globulin (Doi et al. 2007). 
Another example can be found in the hormone feedback 
loops in thyroid function in rats (Hard 2018), explaining 
why many substances that induce rodent thyroid tumors do 
not act as carcinogens in humans (Boobis et al. 2016). Thus, 
the use of including AOPs in safety assessment can be to 
support the human relevance of the effects observed in a test 
species. In the tiered approach for food additive evaluations 
proposed by EFSA (2012), mode-of-action studies may also 
be indicated in tier 3 when the results from regular OECD-
based guideline studies in tier 2 trigger such additional 
studies, usually on a case-by-case basis. When describing 
the role of mode-of-action in the guidance document, the 
respective section indicates its use to support the relevance 
of findings in animals for humans. More specifically, it 
is mentioned that such studies can examine the mode-of-
action for carcinogenic effects or other endpoints, includ-
ing endocrine disruption. EFSA also points out that these 
studies should use appropriate mode-of-action frameworks 
when assessing the data. This illustrates that in the currently 
applicable EFSA guidance for food additive evaluation, the 
AOP concept is included in the form of consideration of 
the mode-of-action, particularly for supporting selection of 
the correct in vitro system or animal model for the human 
situation. Taking this into account, one could foresee that 
including the AOP concept in the safety evaluation of food 
additives may also provide support for defining AOP-based 
definition of chemical-specific adjustment factors that devi-
ate from the default uncertainty factors for interspecies or 
intraspecies differences in toxicodynamics.
The overview of critical effects used in the safety evalu-
ation of food additives presented in this study provides a 
way forward to match the current use of the mode-of-action 
concept in safety evaluation of food additives and future 
AOP development. The data obtained revealed that often 
such detailed analysis of the mode-of-action would not be 
required because for 60% of the food additives, the EFSA/
SCF/JECFA safety evaluations did not identify a PoD for 
adverse effects. This probably reflects that, in contrast to 
other chemicals, such as pesticides, food additives are not 
designed to cause effects. For 22% of the food additives, the 
database for the established list of food additives listed in 
Annex II of Regulation (EC) No 1333/2008 (EC1333/2008), 
as summarized in Table S1 (supplementary information), 
identified specific critical adverse effects in animals. 
Replacement of the current default procedure for safety 
evaluation of food additives, also including 3R-alternative 
testing strategies, will require better use of insights into the 
modes-of-actions for both kinetic as well as dynamic char-
acteristics. AOPs have the potential to provide insights into 
the toxicodynamics of a mode-of-action required to select 
the proper testing models not only for genotoxicity and 
carcinogenicity, as already done on a case-by-case basis, 
but also for other critical adverse effects. Further screening 
of the self-compiled database in Table S1 (supplementary 
information) of the present paper for relevant critical adverse 
effects food additives listed in Annex II of Regulation (EC) 
No 1333/2008 (EC1333/2008), in particular those used for 
establishing ADIs, showed that the most frequent critical 
toxic endpoints used for the safety assessment of food addi-
tives are related to liver and kidney effects. Other critical 
endpoints involved the cardiovascular system, the lymphatic 
system, the central nervous system and the reproductive sys-
tem. AOPs are available for many of these apical endpoints 
in the AOP Wiki. However, they show different degrees of 
maturity, which could hamper their current use for safety 
evaluation purposes. For a number of other adverse out-
comes pertinent to food additives, AOPs are completely 
lacking. This particularly holds true for irritation and/or 
corrosion of the different tissues in the gastrointestinal tract 
as well as for specific types of cancer, such as bladder can-
cer. Therefore, to further advance the use of AOPs in safety 
evaluation of food additives, efforts should be focused on 
developing AOPs for these particular toxicities. While doing 
so, and particularly in view of fit-for-purpose applications 
in the food additives field, quantification of these AOPs 
should be set as a priority. This can be achieved in a num-
ber of ways, such as by applying Bayesian computational 
methods, systems biology approaches and mathematical 
modeling of KE relationships employing machine learning. 
Furthermore, it should be kept in mind that individual AOPs 
are merely pragmatic tools for development and evaluation. 
For real-life applications, such as for the safety evaluation 
of food additives, so-called AOP networks should be used. 
AOP networks basically consist of combinations of indi-
vidual AOPs with different MIEs and shared KEs (Knapen 
et al. 2018; Willett et al. 2018). AOP networks have already 
been proposed for a number of frequently occurring adversi-
ties, including liver steatosis (Mellor et al. 2016). It can be 
anticipated that upon development of such quantified AOP 
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networks for critical effects relevant to the safety assess-
ment of food additives as well as their implementation in 
integrative testing strategies, new avenues will be opened 
for innovative mechanistic safety evaluation approaches in 
the food industry, providing improved reliability while using 
fewer or no animals.
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